AEON Biopharma Inc Dossier
Qualitative Analysis
Business overview
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, for debilitating medical conditions. ABP-450 is being developed as a biosimilar to Botox® (onabotulinumtoxinA) under the 351(k) biosimilar regulatory pathway. The company holds exclusive therapeutic rights to the product across major international markets, including the United States, Canada, the European Union, and the United Kingdom, supported by a globally validated cGMP manufacturing platform through its partner Daewoong Pharmaceutical. Initial development programs target therapeutic indications such as chronic and episodic migraine, cervical dystonia, gastroparesis, and post-traumatic stress disorder (PTSD).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing ABP-450 (prabotulinumtoxinA) as a 351(k) biosimilar to BOTOX (onabotulinumtoxinA) for therapeutic indications to achieve full-label U.S. market entry.
Expected impact: Positions the company to address a therapeutic neurotoxin market exceeding $3.0 billion annually by offering a scientifically validated and clinically comparable alternative to BOTOX.
Pursuing an original, dedicated therapeutics-only Biologics License Application (BLA) for ABP-450.
Expected impact: Enables favorable Average Sales Price (ASP) calculations and tailored reimbursement, discounting, and rebate strategies for payors and providers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides AEON with exclusive development and commercialization rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories, backed by Daewoong's cGMP manufacturing support.
Terms: Includes equity and debt financing arrangements, such as a definitive agreement executed in December 2025 to exchange $15 million of convertible notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 million shares.